Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).


CSE:RVV - Post by User

Revive Therapeutics Ltd > fyi .. hopefully, a favorable PR this week !
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5)
•••
Comment by 1ottrunneron Aug 31, 2021 7:50am
212 Views
Post# 33786794

RE:RE:fyi .. hopefully, a favorable PR this week !

RE:RE:fyi .. hopefully, a favorable PR this week !
cool888 wrote:
cool888 wrote: Should note that the interview article that featured MF, “ reaches over 543,000 executives worldwide, in our chosen industries”
I also signed up for the newsletter to see where our little RVV article sat…Top of the page under Top Headlines.
I say good press, and re affirmative of the good science behind Bucillamine. Not to worry about the length of trial as it seems we’re going the route of anti inflammatory and will most definitely be first in that space. GLTA

https://www.outsourcing-pharma.com/Info/About-us
 


Copied from a Yahoo post. Thx Wolf !!



Morons, these are promotional pieces, this BS isn't picked up, it is being promoted.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities